Rigorous economic analysis to guide critical decisions in health policy.
Health Strategies International (HSI) was founded in 1999 by Elliot Marseille, DrPH, MPP who is its President and sole proprietor. For over two decades, the firm has produced policy-relevant analyses on the economics of a wide range of health topics including HIV/AIDS, essential surgery, tuberculosis, hepatitis C, hepatitis B, teen pregnancy prevention, and gestational diabetes.
HSI's work now focuses on the costs and health outcomes associated with the emerging psychedelic-assisted therapies such as MDMA to treat PTSD and psilocybin to treat major depression. In June, 2021, HSI, in partnership with UC Berkeley and UC San Francisco created the Collaborative for the Economics of Psychedelics (CEP). CEP is the first academic center dedicated to the economics of psychedelic therapies and their integration into mental health care.
Upcoming Events
Elliot Marseille will be presenting at the Interdisciplinary Conference on Psychedelic Research (June 6-8 2024) in the Netherlands on the agenda for research on the economics of psychedelic therapies.
Current Focus
Collaborative for the Economics of Psychedelics (CEP) is a network of health economists and health services researchers dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, CEP seeks to enhance clinical outcomes, and efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit.